Literature DB >> 15947094

Identification of target genes and a unique cis element regulated by IRF-8 in developing macrophages.

Tomohiko Tamura1, Pratima Thotakura, Tetsuya S Tanaka, Minoru S H Ko, Keiko Ozato.   

Abstract

Interferon regulatory factor-8 (IRF-8)/interferon consensus sequence-binding protein (ICSBP) is a transcription factor that controls myeloid-cell development. Microarray gene expression analysis of Irf-8-/- myeloid progenitor cells expressing an IRF-8/estrogen receptor chimera (which differentiate into macrophages after addition of estradiol) was used to identify 69 genes altered by IRF-8 during early differentiation (62 up-regulated and 7 down-regulated). Among them, 4 lysosomal/endosomal enzyme-related genes (cystatin C, cathepsin C, lysozyme, and prosaposin) did not require de novo protein synthesis for induction, suggesting that they were direct targets of IRF-8. We developed a reporter assay system employing a self-inactivating retrovirus and analyzed the cystatin C and cathepsin C promoters. We found that a unique cis element mediates IRF-8-induced activation of both promoters. Similar elements were also found in other IRF-8 target genes with a consensus sequence (GAAANN[N]GGAA) comprising a core IRF-binding motif and an Ets-binding motif; this sequence is similar but distinct from the previously reported Ets/IRF composite element. Chromatin immunoprecipitation assays demonstrated that IRF-8 and the PU.1 Ets transcription factor bind to this element in vivo. Collectively, these data indicate that IRF-8 stimulates transcription of target genes through a novel cis element to specify macrophage differentiation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15947094      PMCID: PMC1895144          DOI: 10.1182/blood-2005-01-0080

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  44 in total

1.  Cutting edge: IFN consensus sequence binding protein/IFN regulatory factor 8 drives the development of type I IFN-producing plasmacytoid dendritic cells.

Authors:  Hideki Tsujimura; Tomohiko Tamura; Keiko Ozato
Journal:  J Immunol       Date:  2003-02-01       Impact factor: 5.422

2.  Regulation of macrophage and neutrophil cell fates by the PU.1:C/EBPalpha ratio and granulocyte colony-stimulating factor.

Authors:  Richard Dahl; Jonathan C Walsh; David Lancki; Peter Laslo; Sangeeta R Iyer; Harinder Singh; M Celeste Simon
Journal:  Nat Immunol       Date:  2003-09-07       Impact factor: 25.606

3.  Gamma interferon triggers interaction between ICSBP (IRF-8) and TEL, recruiting the histone deacetylase HDAC3 to the interferon-responsive element.

Authors:  Takeshi Kuwata; Celine Gongora; Yuka Kanno; Kazuyasu Sakaguchi; Tomohiko Tamura; Tomohiko Kanno; Venkatesha Basrur; Robert Martinez; Ettore Appella; Todd Golub; Keiko Ozato
Journal:  Mol Cell Biol       Date:  2002-11       Impact factor: 4.272

Review 4.  The importance of PU.1 concentration in hematopoietic lineage commitment and maturation.

Authors:  Richard Dahl; M Celeste Simon
Journal:  Blood Cells Mol Dis       Date:  2003 Sep-Oct       Impact factor: 3.039

5.  IRF-4,8 orchestrate the pre-B-to-B transition in lymphocyte development.

Authors:  Runqing Lu; Kay L Medina; David W Lancki; Harinder Singh
Journal:  Genes Dev       Date:  2003-06-27       Impact factor: 11.361

6.  Interferon consensus sequence binding protein (ICSBP; IRF-8) antagonizes BCR/ABL and down-regulates bcl-2.

Authors:  Andreas Burchert; Dali Cai; Lorenz C Hofbauer; Magnus K R Samuelsson; Emily P Slater; Justus Duyster; Markus Ritter; Andreas Hochhaus; Rolf Müller; Martin Eilers; Manuel Schmidt; Andreas Neubauer
Journal:  Blood       Date:  2003-12-04       Impact factor: 22.113

7.  ICSBP/IRF-8 inhibits mitogenic activity of p210 Bcr/Abl in differentiating myeloid progenitor cells.

Authors:  Tomohiko Tamura; Hee Jeong Kong; Chainarong Tunyaplin; Hideki Tsujimura; Kathryn Calame; Keiko Ozato
Journal:  Blood       Date:  2003-08-21       Impact factor: 22.113

8.  The interferon regulatory factor ICSBP/IRF-8 in combination with PU.1 up-regulates expression of tumor suppressor p15(Ink4b) in murine myeloid cells.

Authors:  Martina Schmidt; Juraj Bies; Tomohiko Tamura; Keiko Ozato; Linda Wolff
Journal:  Blood       Date:  2004-02-19       Impact factor: 22.113

9.  A cathepsin L isoform that is devoid of a signal peptide localizes to the nucleus in S phase and processes the CDP/Cux transcription factor.

Authors:  Brigitte Goulet; Amos Baruch; Nam-Sung Moon; Madeleine Poirier; Laurent L Sansregret; Ann Erickson; Matthew Bogyo; Alain Nepveu
Journal:  Mol Cell       Date:  2004-04-23       Impact factor: 17.970

10.  ICSBP is essential for the development of mouse type I interferon-producing cells and for the generation and activation of CD8alpha(+) dendritic cells.

Authors:  Giovanna Schiavoni; Fabrizio Mattei; Paola Sestili; Paola Borghi; Massimo Venditti; Herbert C Morse; Filippo Belardelli; Lucia Gabriele
Journal:  J Exp Med       Date:  2002-12-02       Impact factor: 14.307

View more
  53 in total

1.  Leukocyte cathepsin C deficiency attenuates atherosclerotic lesion progression by selective tuning of innate and adaptive immune responses.

Authors:  Veronica Herías; Erik A L Biessen; Cora Beckers; Dianne Delsing; Mengyang Liao; Mat J Daemen; Christine C T N Pham; Sylvia Heeneman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-11-13       Impact factor: 8.311

2.  An osteopontin/CD44 immune checkpoint controls CD8+ T cell activation and tumor immune evasion.

Authors:  John D Klement; Amy V Paschall; Priscilla S Redd; Mohammed L Ibrahim; Chunwan Lu; Dafeng Yang; Esteban Celis; Scott I Abrams; Keiko Ozato; Kebin Liu
Journal:  J Clin Invest       Date:  2018-11-05       Impact factor: 14.808

Review 3.  The IRF family, revisited.

Authors:  A Paun; P M Pitha
Journal:  Biochimie       Date:  2007-02-20       Impact factor: 4.079

4.  The feedback phase of type I interferon induction in dendritic cells requires interferon regulatory factor 8.

Authors:  Prafullakumar Tailor; Tomohiko Tamura; Hee Jeong Kong; Toru Kubota; Mayumi Kubota; Paola Borghi; Lucia Gabriele; Keiko Ozato
Journal:  Immunity       Date:  2007-08-16       Impact factor: 31.745

5.  Inducible deposition of the histone variant H3.3 in interferon-stimulated genes.

Authors:  Tomohiko Tamura; Matthew Smith; Tomohiko Kanno; Hormuzdiyer Dasenbrock; Akira Nishiyama; Keiko Ozato
Journal:  J Biol Chem       Date:  2009-02-25       Impact factor: 5.157

6.  IFN regulatory factor 8 represses GM-CSF expression in T cells to affect myeloid cell lineage differentiation.

Authors:  Amy V Paschall; Ruihua Zhang; Chen-Feng Qi; Kankana Bardhan; Liang Peng; Geming Lu; Jianjun Yang; Miriam Merad; Tracy McGaha; Gang Zhou; Andrew Mellor; Scott I Abrams; Herbert C Morse; Keiko Ozato; Huabao Xiong; Kebin Liu
Journal:  J Immunol       Date:  2015-02-02       Impact factor: 5.422

Review 7.  IRF8 regulates myeloid and B lymphoid lineage diversification.

Authors:  Hongsheng Wang; Herbert C Morse
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

8.  The leukemia-associated fusion protein Tel-platelet-derived growth factor receptor β (Tel-PdgfRβ) inhibits transcriptional repression of PTPN13 gene by interferon consensus sequence binding protein (Icsbp).

Authors:  Weiqi Huang; Liping Hu; Ling Bei; Elizabeth Hjort; Elizabeth A Eklund
Journal:  J Biol Chem       Date:  2012-01-18       Impact factor: 5.157

9.  Estrogen receptor signaling promotes dendritic cell differentiation by increasing expression of the transcription factor IRF4.

Authors:  Esther Carreras; Sean Turner; Mark Barton Frank; Nicholas Knowlton; Jeanette Osban; Michael Centola; Chae Gyu Park; Amie Simmons; José Alberola-Ila; Susan Kovats
Journal:  Blood       Date:  2009-10-30       Impact factor: 22.113

10.  Developmental regulation of synthesis and dimerization of the amyloidogenic protease inhibitor cystatin C in the hematopoietic system.

Authors:  Yuekang Xu; Petra Lindemann; Javier Vega-Ramos; Jian-Guo Zhang; Jose A Villadangos
Journal:  J Biol Chem       Date:  2014-02-25       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.